LCTX
What one share of Lineage Cell Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. Certain diseases and medical events can arise from the loss of critical cellular activity and lead to devastating or difficult-to-treat conditions or impairments.
Lineage Cell Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.05 |
|---|---|
| Profit | −$0.13 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.10 |
| Cash and investments | $0.20 |
| Book value | $0.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $0.09 | −$0.15 | $0.00 | $0.00 | — | $0.43 |
| 2023 | $0.05 | −$0.12 | $0.00 | −$0.17 | — | $0.36 |
| 2024 | $0.05 | −$0.09 | $0.00 | −$0.12 | — | $0.36 |
| 2025 | $0.06 | −$0.28 | $0.00 | −$0.08 | — | $0.18 |